HVO
GOODhVIVO Provides Trading Update Ahead of H1 2025 Results
The biotechnology company announces a trading update ahead of its half-year results, with plans for an investor presentation.
hVIVO
10.00GBX
-1.96%
Market Cap
73.88M
Volume
2.12M
63% of avg
P/E Ratio
0.06
EPS (TTM)
1.69
Beta
1.04
Day Range
9.85p - 10.50p
52 Week Range
6.50p10.00p31.00p
10.00p
Upcoming Events
HVO
NEUTRALhVIVO Announces Change in Shareholding
The healthcare company has received a notification of a change in shareholding.
HVO
NEUTRALhVIVO Announces Positive Results from Client's Phase 2b Field Study
The biotechnology company reports positive results from a client's clinical trial, providing laboratory services and participant recruitment support.
HVO
NEUTRALhVIVO Directors Increase Shareholdings
The healthcare company's CEO and CFO have purchased additional shares in the business, demonstrating their confidence in the firm's growth prospects.
HVO
BADhVIVO Faces Headwinds as Trials Cancelled and Postponed
The biotechnology company faces challenges as it reports significant contract cancellations and postponements, along with broader industry headwinds, casting uncertainty over its FY25 revenue outlook.
HVO
NEUTRALhVIVO Appoints New Independent Non-Executive Director
The healthcare company has appointed a new Independent Non-Executive Director with extensive experience in the sector.
HVO
NEUTRALhVIVO Provides Annual Report and AGM Details
The healthcare company has released its annual report and notice of AGM, along with announcing the departure of a non-executive director.
HVO
BADhVIVO Announces Discounted Equity Raise for Employee Options
The biotechnology company announced a discounted equity raise to allow employees to exercise options, raising concerns about its financial position.
HVO
GOODhVIVO Reports Record Revenue and EBITDA in 2024 Final Results
The clinical research organization reported record revenue and EBITDA for 2024, with strong cash generation. However, near-term challenges include acquisition integration and expected margin pressure.
HVO
NEUTRALhVIVO Announces Director Disclosure Update
The biotechnology company provides an update on a director's disclosure related to another company they are involved with.